Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
European Journal of Nuclear Medicine and Molecular Imaging|November 29, 2019
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-upJohanna Maffey-Steffan, Lorenza Scarpa, Anna Svirydenka, et al.
Wiener Klinische Wochenschrift|February 3, 2016
Austrian recommendations on Targeted Hormone Therapy for metastatic, castration-resistant prostate cancerAnton Ponholzer, Wolfgang Loidl, Jasmin Bektic, et al.
International Journal of Molecular Sciences|June 6, 2013
Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivoIris E Eder, Martina Egger, Hannes Neuwirt, et al.
BJU International|March 7, 2008
Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortalityGeorg Bartsch, Wolfgang Horninger, Helmut Klocker, et al.
World Journal of Urology|October 14, 2022
Transurethral resection of the prostate in 85+ patients: a retrospective, multicentre studyMichael Lotterstätter, Stephan Seklehner, Florian Wimpissinger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 16, 2015
(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?Francesco Ceci, Christian Uprimny, Bernhard Nilica, et al.
The Prostate|September 26, 2006
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328Hannes Steiner, Ilaria T Cavarretta, Patrizia L Moser, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 3, 2024
Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancerGiulia Santo, Gianpaolo Di Santo, Anna Sviridenko, et al.
Biomedicines|August 27, 2021
Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate CancerMichael Ladurner, Manuel Wieser, Andrea Eigentler, et al.
European Urology|March 2, 2010
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detectionFlip H Jansen, Ron H N van Schaik, Joep Kurstjens, et al.
Pageof 8